Stealth BioTherapeutics Joins the Rare Disease Company Coalition
On July 7, 2021, Stealth BioTherapeutics Corp (NASDAQ: MITO) announced its membership in the Rare Disease Company Coalition, aimed at developing therapies for rare diseases. CEO Reenie McCarthy expressed enthusiasm for collaborating with other companies to address challenges in rare disease treatment development. The coalition will advocate for favorable drug policies and regulations to support innovation while highlighting the unique difficulties faced in rare disease drug discovery. Stealth focuses on mitochondrial dysfunction therapies, with candidates like elamipretide targeting rare genetic disorders.
- Membership in the Rare Disease Company Coalition aligns with company goals.
- Collaboration may enhance advocacy for supportive drug policies.
- Focus on mitochondrial dysfunction has promising market potential.
- None.
BOSTON, July 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has joined the Rare Disease Company Coalition, an alliance of life science companies committed to discovering, developing, and delivering rare disease treatments for the patients they collectively serve.
"We are thrilled to be a part of the first-of-its-kind Rare Disease Company Coalition, which is focused on supporting rare disease patients through the development of innovative therapeutics," said Reenie McCarthy, Chief Executive Officer at Stealth. "We look forward to working with the other inspiring companies to foster greater understanding of the unique challenges and circumstances associated with the development of rare disease treatments."
The Coalition will engage with policy stakeholders to advocate for impactful drug and healthcare policies and regulations currently under discussion, including prescription drug pricing, to highlight the consequences that blanket legislation can have on continued innovation for rare disease treatments.
About Rare Disease Company Coalition
The Rare Disease Company Coalition represents life science companies committed to discovering, developing and delivering rare disease treatments for the patients we serve. As an education and advocacy-focused coalition of companies, our goal is to inform policymakers of the unique challenges and promises of rare disease drug discovery, development and manufacturing for small population sizes in order for critical innovation to continue. To achieve this goal, we will use our unified voice to advocate for long-term, consistent, equitable and sustainable government policies that enable life science companies to continue to bring hope and provide access to approved treatments to people living with rare diseases. For more information, please visit rarecoalition.com
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-joins-the-rare-disease-company-coalition-301327067.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
What is the recent announcement by Stealth BioTherapeutics?
How does the Rare Disease Company Coalition benefit Stealth BioTherapeutics?
What is the focus of Stealth BioTherapeutics' therapies?
What is MITO's lead product candidate?
What diseases does elamipretide target?
